- Home
- ELWS vs LYRA Comparison
ELWS vs LYRA Comparison
Compare ELWS & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- LYRA
- Stock Information
- Founded
- ELWS 2018
- LYRA 2005
- Country
- ELWS Japan
- LYRA United States
- Employees
- ELWS N/A
- LYRA N/A
- Industry
- ELWS
- LYRA Medical/Dental Instruments
- Sector
- ELWS
- LYRA Health Care
- Exchange
- ELWS Nasdaq
- LYRA Nasdaq
- Market Cap
- ELWS 12.1M
- LYRA 11.3M
- IPO Year
- ELWS 2023
- LYRA 2020
- Fundamental
- Price
- ELWS $3.19
- LYRA $7.51
- Analyst Decision
- ELWS
- LYRA Hold
- Analyst Count
- ELWS 0
- LYRA 1
- Target Price
- ELWS N/A
- LYRA $16.00
- AVG Volume (30 Days)
- ELWS 182.1K
- LYRA 39.0K
- Earning Date
- ELWS 09-30-2025
- LYRA 11-11-2025
- Dividend Yield
- ELWS N/A
- LYRA N/A
- EPS Growth
- ELWS N/A
- LYRA N/A
- EPS
- ELWS N/A
- LYRA N/A
- Revenue
- ELWS $3,083,071.00
- LYRA $770,000.00
- Revenue This Year
- ELWS N/A
- LYRA N/A
- Revenue Next Year
- ELWS N/A
- LYRA $123.83
- P/E Ratio
- ELWS N/A
- LYRA N/A
- Revenue Growth
- ELWS 145.52
- LYRA N/A
- 52 Week Low
- ELWS $1.64
- LYRA $3.81
- 52 Week High
- ELWS $10.50
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- ELWS 56.54
- LYRA 52.58
- Support Level
- ELWS $2.60
- LYRA $6.55
- Resistance Level
- ELWS $3.40
- LYRA $8.75
- Average True Range (ATR)
- ELWS 0.32
- LYRA 0.54
- MACD
- ELWS 0.09
- LYRA 0.15
- Stochastic Oscillator
- ELWS 66.13
- LYRA 35.03
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.